Pharmacokinetics of buspirone in autistic children

Journal of Clinical Pharmacology
David J EdwardsJacob V Aranda

Abstract

Buspirone is used to treat generalized anxiety disorder in children and may be useful in developmental disorders in which brain serotonin synthesis is altered. Autistic children (13 boys, 7 girls) were given a single oral dose of 2.5 mg (2-3 years) or 5.0 mg (4-6 years). Blood was collected for 8 hours, and plasma was assayed for buspirone and its metabolite 1-pyrimidinylpiperazine (1-PP). The peak concentration of buspirone averaged 1141 +/- 748 pg/mL with a time to maximum concentration of 0.8 hours. Half-life was 1.6 +/- 0.3 hours. Peak concentrations of 1-PP were 4.5-fold higher than for buspirone. Girls had higher peak concentrations (1876 vs 746 pg/mL) for buspirone and a lower peak 1-PP/buspirone concentration ratio. These results suggest that buspirone is rapidly absorbed and eliminated in young children with extensive metabolism to 1-PP. Plasma concentrations with 2.5- to 5.0-mg doses were similar to those observed in older children receiving 7.5- to 15-mg doses.

References

Jul 1, 1981·Clinical Pharmacology and Therapeutics·R E KatesD C Harrison
May 1, 1995·Clinical Pharmacology and Therapeutics·M P DucharmeD J Edwards
Jul 1, 1996·Journal of Clinical Pharmacology·M MochonB A Kaiser
Jul 15, 1998·Clinical Pharmacology and Therapeutics·T S LambergP J Neuvonen
Sep 5, 1998·Clinical Pharmacology and Therapeutics·J C GorskiS D Hall
Jan 1, 1999·Clinical Pharmacology and Therapeutics·J J LiljaP J Neuvonen
May 13, 1999·Clinical Pharmacokinetics·I Mahmood, C Sahajwalla
Mar 10, 2000·Journal of Clinical Pharmacology·M E Krecic-ShepardJ B Schwartz
Jul 17, 2001·Journal of Clinical Pharmacology·A Sakr, M Andheria
Jan 5, 2002·Journal of Clinical Pharmacology·M D ReedUNKNOWN Pediatric Pharmacology Research Unit Network
Nov 18, 2003·Nature Reviews. Neuroscience·Patricia GasparLuc Maroteaux
Feb 10, 2004·CNS Spectrums·Christer AllgulanderUNKNOWN World Council of Anxiety
Dec 21, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mary F PainePaul B Watkins
Mar 8, 2005·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Sreenivasa R ChandanaDiane C Chugani

❮ Previous
Next ❯

Citations

Sep 23, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jeremy Veenstra-VanderWeele, Randy D Blakely
Jan 10, 2016·The Journal of Pediatrics·Diane C ChuganiUNKNOWN Autism Center of Excellence Network
Sep 11, 2009·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·Osman SabuncuogluMeral Berkem
Nov 19, 2015·Neuroscience·C L MullerJ Veenstra-VanderWeele
Dec 3, 2014·Pediatric Neurology·Ahmad Ghanizadeh, Anaheed Ayoobzadehshirazi
Dec 16, 2016·Biopharmaceutics & Drug Disposition·Jean-Marie NicolasAnna-Lena Ungell
Sep 17, 2014·Annals of Biomedical Engineering·Thomas P AndriacchiConstance R Chu
Nov 15, 2019·Journal of Autism and Developmental Disorders·Robyn P ThomChristopher J McDougle

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.